^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Osteosarcoma
    Drug:Shan Ke Yu (socazolimab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    First-in-maintenance therapy for localized high-grade osteosarcoma: an open-label phase I/II trial of the anti-PD-L1 antibody ZKAB001

    Published date:
    12/05/2022
    Excerpt:
    24-month EFS was 71.4% (95% CI: 47.2-86.0) and 2-year OS was 100%. Preliminary efficacy data showed EFS benefits in patients with PD-L1 positive or an MSI-H sub-population….Switching to maintenance using ZKAB001 showed an acceptable safety profile and provided preliminary evidence of clinical activity in localized osteosarcoma patients.
    DOI:
    10.1158/1078-0432.CCR-22-2470